Patents by Inventor Gary Witherell

Gary Witherell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating renal cell carcinoma
    Patent number: 8012465
    Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Laurence Elias, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 7432047
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 7, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 7285383
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: October 23, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20070218470
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: October 4, 2006
    Publication date: September 20, 2007
    Inventors: Vincent Miles, Michael Mathews, Michael Katze, Julia Watson, Gary Witherell
  • Methods for treating renal cell carcinoma
    Publication number: 20070014765
    Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.
    Type: Application
    Filed: January 27, 2006
    Publication date: January 18, 2007
    Applicant: Chiron Corporation
    Inventors: Laurence Elias, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 7045284
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: May 16, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20050265975
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: August 1, 2005
    Publication date: December 1, 2005
    Inventors: Vincent Miles, Michael Mathews, Michael Katze, Julia Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20040254140
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: June 14, 2004
    Publication date: December 16, 2004
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6824976
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 30, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6777179
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: August 17, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6667152
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: December 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6623961
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: September 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20030144226
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 27, 2002
    Publication date: July 31, 2003
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6579674
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: June 17, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20020165194
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 28, 2002
    Publication date: November 7, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20020160976
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 31, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Publication number: 20020160977
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Application
    Filed: March 28, 2002
    Publication date: October 31, 2002
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Method for selective inactivation of viral replication
    Patent number: 6156496
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: December 5, 2000
    Assignee: Ribogene, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell